Alnylam Pharma (ALNY) Tops Q4 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. PLTR
3. DOX
4. AMD
5. VRTX
6. CRWD
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Alnylam Pharma (ALNY) Tops Q4 EPS by 24c

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity

February 6, 2020 8:00 AM EST

Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively

As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with Patisiran

Observed Strong Initial Demand for GIVLAARI (givosiran) in the U.S., with 13 Start Forms Received in First Six Weeks after FDA Approval

Reported Third Positive 2019 Phase 3 Result with Lumasiran and Initiated Rolling Submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA)

Initiated HELIOS-B Phase 3 Study of... More